Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Trial To Evaluate The Safety And Efficacy Of Specific Immunotherapy, Recombinant Idiotype Conjugated To KLH With GM-CSF, Compared To Non-Specific Immunotherapy, KLH With GM-CSF, In Patients With Follicular Non-Hodgkin's Lymphoma

NCT00017290 is registered in ClinicalTrials.gov with Genitope Corporation as lead sponsor.

NCT NCT00017290
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00017290 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Trial To Evaluate The Safety And Efficacy Of Specific Immunotherapy, Recombinant Idiotype Conjugated To KLH With GM-CSF, Compared To Non-Specific Immunotherapy, KLH With GM-CSF, In Patients With Follicular Non-Hodgkin's Lymphoma
Lead sponsor
Genitope Corporation
Phase
Phase 3
Overall status
Unknown status
Start date
November 30, 2000
Completion date
Not reported
Enrollment
Not reported
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma